Journal
CLINICAL IMMUNOLOGY
Volume 155, Issue 2, Pages 160-175Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2014.10.002
Keywords
Anti-CD20 chimeric antigen receptor (CAR) T cells; Refractory advanced; Diffuse large B-cell lymphoma (DLBCL); Delayed toxicities
Categories
Funding
- National Natural Science Foundation of China [31270820, 81230061, 81121004, 81402566]
- National Basic Science and Development Programme of China [2012CB518103, 2012AA020502, 2013BAI01B00]
Ask authors/readers for more resources
We conducted a trial testing a CD20-specific CAR coupled with CD137 and the CD3 zeta moiety in patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL). Seven patients were enrolled. One of the two patients with no bulky tumor obtained a 14-month durable and ongoing complete remission by cell infusion only, and another attained a 6-month tumor regression. Four of five patients with bulky tumor burden were evaluable for clinical efficacy, three of which attained 3- to 6-month tumor regression. Delayed toxicities related to cell infusion are directly correlated to tumor burden and tumor-harboring sites, and mainly included cytokine release symptoms, tumor lysis symptoms, massive hemorrhage of the alimentary tract and aggressive intrapulmonary inflammation surrounding extranodal lesions. These results show firstly that anti-CD20 CART cells can cause prolonged tumor regression in combination with debulking conditioning regimens for advanced DLBCL. This study is registered at www.clinicaltrials.gov as NCT01735604. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available